For this top piece, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
A woman I’ll call Rachel (a real patient, name changed) sat across from me on a video consult last fall holding a sticky note with three numbers on it: 0.25, 0.5, 1.0. Her sister had been on brand-name Wegovy for six months. Rachel’s insurance wouldn’t cover it. She’d found a compounded semaglutide program online, and she wanted to know, essentially, whether she was about to inject herself with something sketchy. That conversation, which lasted about 25 minutes, is the conversation I find myself having three or four times a week. This article is, more or less, the written version.
The Drug Itself, and Why There Are Two Pathways to Get It
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It came to market as Ozempic in 2017 for type 2 diabetes and as Wegovy in 2021 for chronic weight management. Both are FDA-approved finished products manufactured at industrial scale.
Compounded semaglutide uses the same active pharmaceutical ingredient, prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription. It is not FDA-approved as a finished product. That last sentence matters, and I’ll come back to it.
The compounding pathway is governed by section 503A of the Federal Food, Drug, and Cosmetic Act, plus a patchwork of state pharmacy regulations. Compounding itself is nothing exotic. Pharmacies have compounded medications for decades across dozens of drug classes. What’s new is the scale of patient interest in compounded GLP-1s, driven almost entirely by price.
What the Clinical Trials Actually Showed
The evidence base for semaglutide is built on the brand-name finished product. That’s an important caveat, but it’s also the starting point for any honest conversation about the drug.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, alongside lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). Those are means. Individual responders ranged widely, from roughly 5% to over 20%. STEP-3 layered in intensive behavioral therapy and pushed results slightly higher. STEP-5 extended follow-up to 104 weeks and showed sustained weight reduction in the active arm.
On the diabetes side, the SUSTAIN program established the glycemic and cardiovascular signal at lower doses (0.5 mg and 1.0 mg weekly, with 2.0 mg added in SUSTAIN FORTE). SUSTAIN-6 (Marso SP et al.) reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population.
Here’s where the caveat hits: none of those registrational trials used compounded preparations. The pharmacological effect of the same active ingredient is expected to track similarly, but compounded semaglutide has not been studied as a finished product in those trials. A careful clinician tells you that upfront. An irresponsible one glosses over it.
The Titration Schedule (and Why Patience Is the Whole Game)
The label-standard titration from the STEP trials is a five-step escalation:
- 0.25 mg weekly for 4 weeks
- 0.5 mg weekly for 4 weeks
- 1.0 mg weekly for 4 weeks
- 1.7 mg weekly for 4 weeks
- 2.4 mg weekly (maintenance)
Full escalation takes 16 to 17 weeks if every step is held for the minimum four weeks. Most compounded programs follow the same milligram increments, though the concentration and volume of the preparation vary by pharmacy. The dose in milligrams is what matters clinically, not how many units you draw into a syringe. If you’re switching programs, confirm the milligram dose at each step.
The boring truth is that titration is where most of the patient experience is made or broken. A patient struggling with nausea at 0.5 mg can stay there for an extra four weeks. A patient doing well clinically at 1.7 mg can stay there rather than pushing to 2.4 mg. This is a clinical decision, not a checkbox. The best programs treat it that way.
Storage: standard refrigeration, 36 to 46°F. Limited room-temperature time is fine for transport. Injection-site rotation between abdomen, thigh, and upper arm reduces local irritation. Pick a consistent day of the week and stick with it.
Side Effects: What’s Common, What’s Rare, What’s Serious
The gastrointestinal side effects dominate the first eight to twelve weeks. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These were reported across both STEP and SUSTAIN programs and show up consistently in real-world cohorts. Most are mild to moderate and resolve with continued therapy or a temporary dose hold.
Less common but clinically significant:
- Gallbladder events, especially with rapid weight loss. (Think of the gallbladder like a little bag that doesn’t appreciate sudden changes in the amount of fat passing through its neighborhood.)
- Acute pancreatitis, rare but serious. Persistent severe abdominal pain radiating to the back warrants immediate evaluation.
- Thyroid C-cell tumors: seen in rodent studies, not replicated in humans. Both the Wegovy and Ozempic labels carry a boxed warning on this, plus a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because the insulin effect is glucose-dependent. The risk jumps when combined with insulin or sulfonylureas, and the fix is adjusting those other agents.
The Cost Question
Brand-name Wegovy and Ozempic list above $1,300 per month in the US. Cash-pay at most retail pharmacies runs $1,000 to $1,400. Insurance coverage for the weight-management indication is, charitably, inconsistent.
Compounded programs in compliant telehealth structures price substantially lower. HealthRX, which operates under LegitScript certification, publishes rates of $179.99 to $279.99 per month depending on dose, available in 44 US states. That’s a meaningful difference, and it’s structural, not promotional. Brand-name finished products carry the cost of manufacturing scale-up, regulatory submissions, post-marketing surveillance, and the commercial margin that funds Novo Nordisk’s next generation of R&D. Compounded preparations are produced through a different regulatory pathway with a different cost structure. Both of those facts can be true simultaneously.
HSA and FSA reimbursement for compounded semaglutide depends on the plan and the invoicing format the program provides. Confirm before you enroll, not after.
Compounded vs. Brand-Name: What the Difference Actually Means
I think the most useful way to frame this is not as “brand-name good, compounded sketchy” or “compounded identical, just cheaper.” It’s a comparison of supply pathways for the same active ingredient, with three practical differences:
First, the clinical evidence from STEP and SUSTAIN was generated with the brand-name product. It informs our expectations for compounded semaglutide but doesn’t directly extend to it.
Second, the manufacturing oversight model differs. Compounded pharmacies are regulated by state boards of pharmacy (and, for 503B outsourcing facilities, by the FDA under a separate framework). That’s not the same as the finished-product manufacturing oversight applied to Novo Nordisk.
Third, adverse-event surveillance is less systematic for compounded preparations. Patients on brand-name products are captured in post-marketing safety databases more reliably.
None of those differences means compounded semaglutide is inherently unsafe. They mean a careful patient should understand the framework rather than flattening the conversation into a price comparison. Readers who want a deeper walk-through of the clinical and practical questions that come up in a real intake conversation can read this top piece, which covers them in a format designed to make the actual clinician conversation more productive.
When You Need to Pick Up the Phone
Self-management has limits. These scenarios warrant a direct conversation with your prescribing clinician:
- Persistent severe abdominal pain, especially with radiation to the back or fever
- Inability to keep down fluids for more than 24 hours, signs of dehydration, or persistent vomiting
- New gallbladder symptoms: right upper quadrant pain after meals, jaundice
- New or worsening reflux that doesn’t respond to meal-timing adjustments
- Mood changes, including new or worsening depressive symptoms
- Pregnancy, planned pregnancy, or breastfeeding (before the next dose, not after)
- Personal or family history of medullary thyroid carcinoma or MEN2 that wasn’t surfaced at intake (if it wasn’t, have that conversation immediately)
- Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering agents
- Concurrent medications with narrow therapeutic windows (warfarin, for instance), since slowed gastric emptying can affect absorption
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy?
The active ingredient, semaglutide, is the same. The regulatory category, manufacturing pathway, and finished-product status are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last?
STEP-1 captured 68 weeks of treatment. STEP-5 extends to 104 weeks. Clinical experience now goes beyond two years. Duration is individualized based on goals, response, and tolerability.
Is the weight reduction sustained after stopping?
STEP-4 showed significant regain in the group switched to placebo after a lead-in period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on the lifestyle changes a patient has consolidated during treatment.
Do I need labs to start?
A well-run program will document baseline labs, typically a metabolic panel, lipid panel, A1c, and sometimes a thyroid panel. The specific set depends on your clinical picture.
Is semaglutide right for everyone?
No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A real intake conversation surfaces these before therapy begins.
What if I’m coming from a nutrition-first approach?
Most of the patients I see in this space already eat reasonably well. The medication changes the hormonal environment around appetite. It doesn’t replace the need for adequate protein, fiber, and hydration, and in fact those become more important during rapid weight loss to preserve lean mass.
Can I switch between compounded and brand-name semaglutide?
In principle, yes, as long as the milligram dose is matched. Confirm with your clinician when transitioning.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
